The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict OraSure Technologies' revenues will expand 17.6% and EPS will remain in the red.
The average estimate for revenue is $22.4 million. On the bottom line, the average EPS estimate is -$0.09.
Last quarter, OraSure Technologies tallied revenue of $20.9 million. GAAP reported sales were 20% higher than the prior-year quarter's $17.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at -$0.07. GAAP EPS were -$0.07 for Q1 compared to -$0.06 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 65.6%, 90 basis points better than the prior-year quarter. Operating margin was -17.4%, 270 basis points worse than the prior-year quarter. Net margin was -15.5%, 60 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $97.2 million. The average EPS estimate is -$0.25.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 197 members out of 218 rating the stock outperform, and 21 members rating it underperform. Among 57 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 49 give OraSure Technologies a green thumbs-up, and eight give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on OraSure Technologies is outperform, with an average price target of $13.58.
The healthcare investing landscape is littered with also-rans and a few major winners. Is OraSure Technologies performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.
- Add OraSure Technologies to My Watchlist.